BioCentury | Apr 1, 2020
Distillery Therapeutics

FLNA identified as a target for epilepsy associated with focal cortical dysplasia type II

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Inhibiting the actin-binding protein FLNA could prevent or treat epilepsy associated with focal cortical dysplasia type II, a cerebral developmental malformation. Levels of FLNA protein in cortical tissue from 12...
BC Innovations | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BC Week In Review | Feb 7, 2019
Clinical News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments follow a Jan. 31 meeting with FDA to discuss an...
BC Extra | Feb 5, 2019
Company News

Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments Tuesday follow a Jan. 31 meeting with FDA to discuss...
BC Innovations | Dec 12, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Cell culture and mouse studies suggest treatment with cilnidipine or inhibiting DNM1L could help treat MI. Screening of antihypertensive drugs in primary rat cardiac fibroblasts cultured under hypoxic conditions identified that...
BC Innovations | Oct 12, 2018
Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss. CNS synapses that relay signals involved in memory and cognitive function are...
BC Week In Review | Aug 10, 2018
Clinical News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Aug. 6 after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan...
BC Extra | Aug 6, 2018
Company News

Pain shifting to AD following fourth Remoxy CRL

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Monday after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan to...
BC Week In Review | Dec 8, 2017
Clinical News

Pain reports Phase I data for AD candidate PTI-125

In October, Pain Therapeutics Inc. (NASDAQ:PTIE) reported data from a Phase I trial of Alzheimer's disease candidate PTI-125 in 24 healthy volunteers showing that single oral doses of 50, 100 and 200 mg were well...
BC Innovations | Apr 14, 2016
Product R&D

AACR by the numbers

See Figure: Top indications See Table: Novel cancer targets at AACR 2016 See Figure: Top institutions and companies See Figure: Top targets Tables Novel cancer targets at AACR 2016 Breast cancer amplified sequence 1 (BCAS1)...
Items per page:
1 - 10 of 17